Trump Administration Takes Stake in USA Rare Earth to Boost U.S. Critical Minerals Supply 
Exxon Mobil’s XTO Energy Explores Sale of Eagle Ford Shale Assets in South Texas 
Shell Plc Downgraded by RBC as Market Headwinds Pressure Valuation 
U.S. Lawmakers Demand Scrutiny of TikTok-ByteDance Deal Amid National Security Concerns 
Elon Musk Shares Bold Vision for AI, Robots, and Space at Davos 
Trump Lawsuit Against JPMorgan Signals Rising Tensions Between Wall Street and the White House 
Ericsson Plans SEK 25 Billion Shareholder Returns as Margins Improve Despite Flat Network Market 
Baker Hughes Reports 11% Rise in Q4 Adjusted Profit Driven by LNG Demand 
Hermès Menswear Marks Historic Transition as Véronique Nichanian Bids Farewell in Paris 
LVMH Succession Uncertainty Raises Governance Concerns Among Shareholders 
SEC Drops Gemini Enforcement Case After Full Repayment to Earn Investors 
Microsoft Restores Microsoft 365 Services After Widespread Outage 
Toyota Recalls 162,000 Tundra Vehicles in U.S. Over Multimedia Display Issue 
Embraer Targets Growth as Regional Jet Demand Surges Post-Pandemic 
SAN DIEGO, May 11, 2017 -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced regulatory approvals in select international markets.
Obalon has received notification that it has obtained the necessary regulatory approvals in select Middle East markets to commercialize the Obalon six-month balloon and the associated inflation dispenser. Obalon intends to fulfill an initial order to its Middle East distributor, Bader Sultan, during the second quarter of 2017.
About Obalon Therapeutics, Inc.
Obalon Therapeutics, Inc. (NASDAQ:OBLN) is a San Diego-based company focused on developing and commercializing novel technologies for weight loss. The Obalon management team has over 150 combined years of experience in developing and commercializing novel medical technologies with a track record of financial and clinical excellence. For more information, please visit www.obalon.com.
For Obalon Therapeutics, Inc. Investor Contact: William Plovanic Chief Financial Officer Obalon Therapeutics, Inc. Office: +1 760 607 5103 [email protected] Media: Megan Driscoll EvolveMKD Office Phone: +1 646 517 4220 [email protected]
